Multiple endogenous receptors for secreted growth factors and cytokines on wound-bed cells

The phrase Multiple endogenous receptors for secreted growth factors and cytokines on wound-bed cells is a descriptive term used in pharmacological labeling, specifically for the drug Becaplermin (Regranex), to define its site of action (FDA, Regranex Label). It does not refer to a single molecular target but rather to a collective group of receptors, including platelet-derived growth factor receptors (PDGFR), fibroblast growth factor receptors (FGFR), and epidermal growth factor receptors (EGFR), found on cells within a wound environment (StatPearls, NBK470443). These receptors are essential for the complex biological orchestration of wound healing, mediating signals for cell migration, DNA synthesis, and the deposition of extracellular matrix (PubMed, PMID: 23991417). Therapeutic agents like Becaplermin act as exogenous ligands that bind to and activate specific members of this group, such as PDGFR-alpha and PDGFR-beta, to accelerate the healing of chronic ulcers (DrugBank, DB00049). Because this term describes a physiological context and a broad array of distinct protein families rather than a specific gene or protein, it is considered a non-specific descriptive category in structured pharmacological databases. Consequently, while the individual receptors within this group are valid therapeutic targets, the phrase itself is classified as incorrect for precise molecular target identification.

Other names

Wound-bed growth factor receptorsWound-bed cytokine receptorsGrowth factor receptors in wound healing

Activation of specific cell-surface receptors (such as PDGFR, FGFR, or EGFR) on fibroblasts, endothelial cells, and keratinocytes to trigger intracellular signaling pathways that promote tissue repair and granulation tissue formation.